GeneOne Life Science, Inc.
16
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.3%
1 terminated/withdrawn out of 16 trials
92.3%
+5.8% vs industry average
0%
0 trials in Phase 3/4
33%
4 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
Role: lead
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
Role: lead
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
Role: lead
GLS-5700 in Dengue Virus-Naïve Adults
Role: lead
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
Role: lead
GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery
Role: lead
GLS-5700 in Dengue Virus Seropositive Adults
Role: lead
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
Role: lead
Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers
Role: lead
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Role: lead
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Role: collaborator
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
Role: lead
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Role: lead
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Role: lead
Multiple-Dose Study of VGX-1027 in Healthy Subjects
Role: collaborator
Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects
Role: collaborator
All 16 trials loaded